AU1615701A - Compositions and methods for regulating tumor-associated antigen expression - Google Patents

Compositions and methods for regulating tumor-associated antigen expression

Info

Publication number: AU1615701A
Authority: AU; Australia
Prior art keywords: compositions; methods; associated antigen; antigen expression; regulating tumor
Prior art date: 1999-11-16
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

AU16157/01A

Inventor

James T. Kurnick

Peter J. Van Den Elsen

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Universiteit Leiden

General Hospital Corp

Original Assignee

Universiteit Leiden

General Hospital Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-11-16

Filing date

2000-11-15

Publication date

2001-05-30

2000-11-15 Application filed by Universiteit Leiden, General Hospital Corp filed Critical Universiteit Leiden

2001-05-30 Publication of AU1615701A publication Critical patent/AU1615701A/en

Status Withdrawn legal-status Critical Current

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4271—Melanoma antigens
- A61K40/4272—Melan-A/MART
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0693—Tumour cells; Cancer cells
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Biomedical Technology (AREA)
Animal Behavior & Ethology (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Immunology (AREA)
Epidemiology (AREA)
Zoology (AREA)
Toxicology (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Bioinformatics & Cheminformatics (AREA)
Biotechnology (AREA)
Hematology (AREA)
Wood Science & Technology (AREA)
Oncology (AREA)
Cell Biology (AREA)
Urology & Nephrology (AREA)
Microbiology (AREA)
Gastroenterology & Hepatology (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Analytical Chemistry (AREA)
Pathology (AREA)
General Physics & Mathematics (AREA)
General Engineering & Computer Science (AREA)
Tropical Medicine & Parasitology (AREA)
Physics & Mathematics (AREA)
Food Science & Technology (AREA)

AU16157/01A 1999-11-16 2000-11-15 Compositions and methods for regulating tumor-associated antigen expression Withdrawn AU1615701A (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US16580699P	1999-11-16	1999-11-16
US60165806		1999-11-16
PCT/US2000/031508 WO2001035903A2 (en)	1999-11-16	2000-11-15	Compositions and methods for regulating tumor-associated antigen expression

Publications (1)

Publication Number	Publication Date
AU1615701A true AU1615701A (en)	2001-05-30

Family

ID=22600560

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
AU20432/01A Abandoned AU2043201A (en)	1999-11-16	2000-11-15	Compositions and methods for regulating tumor-associated antigen expression
AU22362/01A Abandoned AU2236201A (en)	1999-11-16	2000-11-15	Compositions and methods for regulating tumor-associated antigen expression
AU16157/01A Withdrawn AU1615701A (en)	1999-11-16	2000-11-15	Compositions and methods for regulating tumor-associated antigen expression

Family Applications Before (2)

Application Number	Title	Priority Date	Filing Date
AU20432/01A Abandoned AU2043201A (en)	1999-11-16	2000-11-15	Compositions and methods for regulating tumor-associated antigen expression
AU22362/01A Abandoned AU2236201A (en)	1999-11-16	2000-11-15	Compositions and methods for regulating tumor-associated antigen expression

Country Status (5)

Country	Link
EP (1)	EP1232178A2 (en)
JP (1)	JP2003515535A (en)
AU (3)	AU2043201A (en)
CA (1)	CA2388517A1 (en)
WO (3)	WO2001035903A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE60200248T2 (en) *	2002-08-01	2005-01-27	Mtm Laboratories Ag	Procedure for solution-based diagnosis
US20100167324A1 (en) *	2005-06-23	2010-07-01	Carney Walter P	Quantitative Assays for Ras p21 in Body Fluids
JP5397692B2 (en) *	2007-11-28	2014-01-22	国立大学法人名古屋大学	Malignant melanoma antigen expression increasing agent and use thereof
CN104984319B (en)	2008-12-19	2025-05-09	武田药品工业株式会社	TFPI inhibitors and methods of use
BR112012023559A2 (en)	2010-03-19	2017-10-17	Baxter Healthcare Sa	tfpi inhibitors and methods of use
CA2867363C (en)	2012-03-21	2023-02-28	Baxter International Inc.	Tfpi inhibitors and methods of use
CA2906587C (en)	2013-03-13	2023-02-14	Health Research, Inc.	Compositions and methods for use of recombinant t cell receptors for direct recognition of tumor antigen
US9550828B2 (en) *	2013-09-05	2017-01-24	Boise State University	Oncostatin M (OSM) antagonists for preventing cancer metastasis and IL-6 related disorders
US11633457B2 (en)	2019-04-11	2023-04-25	Boise State University	Pharmaceutical compositions comprising oncostatin m (OSM) antagonist derivatives and methods of use

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5618715A (en) *	1985-12-20	1997-04-08	Oncogen Limited Partnership	Oncostatin M and novel compositions having anti-neoplastic activity
NZ237533A (en) *	1990-03-29	1992-12-23	Bristol Myers Squibb Co	Monoclonal antibodies which bind to oncostatin m, cell lines producing them
ZA912137B (en) *	1990-03-29	1992-11-25	Oncogen	Monocional antibodies that inhibit growth of kaposi's sarcoma
US6020478A (en) *	1997-02-28	2000-02-01	Incyte Pharmaceuticals, Inc.	Human tumor-associated antigen

2000
- 2000-11-15 AU AU20432/01A patent/AU2043201A/en not_active Abandoned
- 2000-11-15 WO PCT/US2000/031508 patent/WO2001035903A2/en not_active Ceased
- 2000-11-15 JP JP2001538961A patent/JP2003515535A/en not_active Withdrawn
- 2000-11-15 WO PCT/US2000/031511 patent/WO2001036472A2/en not_active Ceased
- 2000-11-15 CA CA002388517A patent/CA2388517A1/en not_active Abandoned
- 2000-11-15 AU AU22362/01A patent/AU2236201A/en not_active Abandoned
- 2000-11-15 EP EP00983714A patent/EP1232178A2/en not_active Withdrawn
- 2000-11-15 WO PCT/NL2000/000835 patent/WO2001036461A2/en not_active Ceased
- 2000-11-15 AU AU16157/01A patent/AU1615701A/en not_active Withdrawn

Also Published As

Publication number	Publication date
AU2043201A (en)	2001-05-30
WO2001036472A2 (en)	2001-05-25
EP1232178A2 (en)	2002-08-21
WO2001036461A3 (en)	2002-01-17
CA2388517A1 (en)	2001-05-25
WO2001036461A2 (en)	2001-05-25
AU2236201A (en)	2001-05-30
WO2001035903A2 (en)	2001-05-25
WO2001036472A3 (en)	2002-01-10
JP2003515535A (en)	2003-05-07

Publication	Publication Date	Title
AU3933200A (en)	2000-11-02	Compositions and methods for controlling pests
AUPQ419099A0 (en)	1999-12-16	Novel compositions and methods
AU2001239947A1 (en)	2001-09-12	Methods and compositions for regulating adipocytes
AU4133701A (en)	2001-06-06	Methods and compositions for peptide synthesis
AU2002354929A1 (en)	2003-03-03	Antibodies specific for nanotubes and related methods and compositions
AU2001293189A1 (en)	2002-04-08	Compositions and methods for regulating apoptosis
AU7859900A (en)	2001-05-10	Compositions and methods for wt1 specific immunotherapy
AU2002364708A1 (en)	2003-06-10	Novel compositions and methods for cancer
AU1940301A (en)	2001-06-12	Tick antigens and compositions and methods comprising them
AU2001275409A1 (en)	2001-12-17	Methods and compositions for controlled polypeptide synthesis
AU2236201A (en)	2001-05-30	Compositions and methods for regulating tumor-associated antigen expression
AU2977500A (en)	2000-08-25	Advanced antigen presentation platform
AU7474100A (en)	2001-04-10	Methods and compositions for reducing immune response
AU6278300A (en)	2001-03-05	Tumor-associated antigen (r11)
AU2001243635A1 (en)	2001-09-24	Methods and compositions for regulating memory consolidation
AU2002218919A1 (en)	2002-07-24	Compositions and methods for regulating receptor clustering
AU6094200A (en)	2001-03-19	Nor gene compositions and methods for use thereof
AU2002337943A1 (en)	2003-05-06	Novel compositions and methods for cancer
AU1597001A (en)	2001-06-06	Compositions and methods for modifying an immune response against tropomyosin
AU7572198A (en)	1998-12-08	Tumor-associated antigen
AU2001251242A1 (en)	2001-10-15	Methods and compositions for regulating memory consolidation
AUPO982097A0 (en)	1997-11-06	Methods and compositions for use therein
AU4328700A (en)	2000-11-02	Pseudomycin antifungal compositions and methods for their use
AU5243899A (en)	2000-02-21	Methods and compositions for using moclobemide
AU8513698A (en)	1999-02-16	Methods and compositions for designing vaccines

Legal Events

Date	Code	Title	Description
2001-09-20	MK6	Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase